Additional file 2: Figure S1. of A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma

Inhibition of MYC sensitizes cells to doxorubicin in RR cells. (a) The left panel showed that RR cells originated from SupM2 and Karpas 299 were treated with varying dosages of MYC inhibitor 10074-G5 for 48 h, and then the cell growth was assessed by the MTS assay. The dosage of 5 μM 10074-G5 was chosen for the following drug combination study. The right panel showed that RR cells were treated with varying dosages of doxorubicin for 48 h, and then the cell growth was assessed by the MTS assay. Fifty and 20 ng/mL doxorubicin were chosen in RR derived from Karpas 299 and SupM2, respectively, for the following drug combination study. (b, c) The cell cycle analysis was performed to assess the Sub G0/1 fraction in RR cells derived from SupM2 induced by 20 ng/mL doxorubicin, 5 μM 10074-G5, or combination of doxorubicin and 10074-G5 for 48 h; Cells with DMSO treatment were included as a control. (d) The PI staining assay was also performed in the experiment described above. (e) RU and RR cells were treated with varying doses of 10074-G5 for 72 h, then followed by the MTS assay to assess the cell growth. (PDF 341 kb)